Articles from Arsenal Biosciences

Company to leverage its enabling technologies to expand into autoimmunity 

-- Bristol Myers Squibb exercises an exclusive license option for ArsenalBio’s AB-4000 series programs --

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Arsenal Biosciences, Inc. (ArsenalBio), a clinical-stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced that Ken Drazan, M.D., ArsenalBio’s CEO and Chairman, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 13, 2025, at 4 p.m. PST. Management will also participate in one-on-one meetings.